JP2019520788A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019520788A5 JP2019520788A5 JP2018550808A JP2018550808A JP2019520788A5 JP 2019520788 A5 JP2019520788 A5 JP 2019520788A5 JP 2018550808 A JP2018550808 A JP 2018550808A JP 2018550808 A JP2018550808 A JP 2018550808A JP 2019520788 A5 JP2019520788 A5 JP 2019520788A5
- Authority
- JP
- Japan
- Prior art keywords
- ryk
- antibody
- seq
- antibody fragment
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 59
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 59
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 36
- 208000012902 Nervous system disease Diseases 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 35
- 210000002569 neuron Anatomy 0.000 claims description 31
- 101710082924 Atypical protein kinase C Proteins 0.000 claims description 20
- 208000025966 Neurological disease Diseases 0.000 claims description 20
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 claims description 19
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 claims description 19
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims description 16
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 16
- 230000009261 transgenic effect Effects 0.000 claims description 16
- 230000027455 binding Effects 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 230000000694 effects Effects 0.000 claims description 13
- 210000003050 axon Anatomy 0.000 claims description 12
- 210000004027 cell Anatomy 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 10
- 239000003550 marker Substances 0.000 claims description 10
- 239000013598 vector Substances 0.000 claims description 9
- 230000007850 degeneration Effects 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 230000003993 interaction Effects 0.000 claims description 6
- 150000007523 nucleic acids Chemical group 0.000 claims description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 5
- 230000012010 growth Effects 0.000 claims description 5
- 238000012216 screening Methods 0.000 claims description 5
- 229940124597 therapeutic agent Drugs 0.000 claims description 5
- 108700024394 Exon Proteins 0.000 claims description 4
- 210000001161 mammalian embryo Anatomy 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 241000699670 Mus sp. Species 0.000 claims description 3
- 108700043304 PKC-3 Proteins 0.000 claims description 3
- 210000000278 spinal cord Anatomy 0.000 claims description 3
- 238000012217 deletion Methods 0.000 claims description 2
- 230000037430 deletion Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 210000004602 germ cell Anatomy 0.000 claims description 2
- 230000002779 inactivation Effects 0.000 claims description 2
- 230000002452 interceptive effect Effects 0.000 claims description 2
- 238000011813 knockout mouse model Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000013011 mating Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 108010054624 red fluorescent protein Proteins 0.000 claims description 2
- 230000009870 specific binding Effects 0.000 claims description 2
- 230000008685 targeting Effects 0.000 claims description 2
- 102000013814 Wnt Human genes 0.000 claims 8
- 150000001413 amino acids Chemical group 0.000 claims 5
- 229940079593 drug Drugs 0.000 claims 2
- 230000001054 cortical effect Effects 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 description 6
- 208000015122 neurodegenerative disease Diseases 0.000 description 6
- 210000002161 motor neuron Anatomy 0.000 description 4
- 210000002804 pyramidal tract Anatomy 0.000 description 4
- 108700028369 Alleles Proteins 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 229940127121 immunoconjugate Drugs 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000001044 sensory neuron Anatomy 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- 102100021262 Frizzled-3 Human genes 0.000 description 1
- 101710140944 Frizzled-3 Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 210000003618 cortical neuron Anatomy 0.000 description 1
- 230000002594 corticospinal effect Effects 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000004295 hippocampal neuron Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000009689 neuronal regeneration Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 210000003594 spinal ganglia Anatomy 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023101322A JP2023130369A (ja) | 2016-03-28 | 2023-06-21 | 抗Ｒｙｋ抗体およびその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662314025P | 2016-03-28 | 2016-03-28 | |
| US62/314,025 | 2016-03-28 | ||
| PCT/US2017/024494 WO2017172733A1 (en) | 2016-03-28 | 2017-03-28 | Anti-ryk antibodies and methods of using the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023101322A Division JP2023130369A (ja) | 2016-03-28 | 2023-06-21 | 抗Ｒｙｋ抗体およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019520788A JP2019520788A (ja) | 2019-07-25 |
| JP2019520788A5 true JP2019520788A5 (cg-RX-API-DMAC10.html) | 2020-05-07 |
| JP7366388B2 JP7366388B2 (ja) | 2023-10-23 |
Family
ID=59966402
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018550808A Active JP7366388B2 (ja) | 2016-03-28 | 2017-03-28 | 抗Ｒｙｋ抗体およびその使用方法 |
| JP2023101322A Pending JP2023130369A (ja) | 2016-03-28 | 2023-06-21 | 抗Ｒｙｋ抗体およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023101322A Pending JP2023130369A (ja) | 2016-03-28 | 2023-06-21 | 抗Ｒｙｋ抗体およびその使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10899839B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3436476A4 (cg-RX-API-DMAC10.html) |
| JP (2) | JP7366388B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR102364249B1 (cg-RX-API-DMAC10.html) |
| CN (1) | CN109563153B (cg-RX-API-DMAC10.html) |
| AU (2) | AU2017245099B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3039910A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2017172733A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3215191B1 (en) | 2014-11-05 | 2024-08-14 | Voyager Therapeutics, Inc. | Aadc polynucleotides for the treatment of parkinson's disease |
| KR20230145206A (ko) | 2014-11-14 | 2023-10-17 | 보이저 테라퓨틱스, 인크. | 조절성 폴리뉴클레오티드 |
| CN114717264A (zh) | 2014-11-14 | 2022-07-08 | 沃雅戈治疗公司 | 治疗肌萎缩性侧索硬化(als)的组合物和方法 |
| US10584337B2 (en) | 2016-05-18 | 2020-03-10 | Voyager Therapeutics, Inc. | Modulatory polynucleotides |
| EP3618839A4 (en) | 2017-05-05 | 2021-06-09 | Voyager Therapeutics, Inc. | COMPOSITIONS AND METHODS OF TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) |
| JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
| CN112424359A (zh) | 2018-05-15 | 2021-02-26 | 沃雅戈治疗公司 | 用于治疗帕金森氏病的组合物和方法 |
| JP7325075B2 (ja) * | 2018-09-21 | 2023-08-14 | 学校法人 埼玉医科大学 | フリズルド３発現細胞の細胞数増加剤若しくは低下剤、糖尿病予防若しくは治療剤、インスリノーマ予防若しくは治療剤、及びインスリン分泌促進剤若しくは分泌抑制剤よりなる群から選択される少なくとも１つの剤をスクリーニングするためのスクリーニング剤、スクリーニング用キット、及びスクリーニング方法 |
| US12281321B2 (en) | 2018-09-28 | 2025-04-22 | Voyager Therapeutics, Inc. | Frataxin expression constructs having engineered promoters and methods of use thereof |
| CN114269379A (zh) * | 2019-06-28 | 2022-04-01 | 加利福尼亚大学董事会 | 用于治疗阿尔茨海默病的方法和组合物 |
| CN117295767A (zh) * | 2020-11-11 | 2023-12-26 | Versapeutics公司 | 针对wnt受体ryk的抗体变体 |
| JP2024535691A (ja) * | 2021-08-18 | 2024-10-02 | ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア | 抗受容体チロシンキナーゼ関連タンパク質（Ｒｙｋ）抗体及びその使用 |
| CN117224689B (zh) * | 2023-11-16 | 2024-02-23 | 上海复宏汉霖生物技术股份有限公司 | 联合抗her2抗体和化疗剂治疗胃癌的用途 |
| CN117447601B (zh) * | 2023-12-22 | 2024-03-08 | 北京索莱宝科技有限公司 | 猪IgM的抗体、抗体组合物及其应用 |
| CN118707101B (zh) * | 2024-07-02 | 2024-12-17 | 安徽德合功生物科技有限公司 | 检测ca125的elisa试剂盒及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040023864A1 (en) * | 2001-05-09 | 2004-02-05 | Steve Roczniak | Method of regulating angiogenesis using ryk protein |
| US7374760B2 (en) * | 2003-05-15 | 2008-05-20 | The University Of Chicago | Methods and compositions for nerve regeneration |
| KR20070094890A (ko) | 2004-10-25 | 2007-09-27 | 머크 앤드 캄파니 인코포레이티드 | 안티 ａｄｄｌ 항체 및 그 용도 |
| MX2008015138A (es) * | 2006-06-02 | 2009-01-28 | Aveo Pharmaceuticals Inc | Proteinas de union al factor de crecimiento de hepatocitos (fch). |
| AU2007285763B2 (en) | 2006-08-18 | 2011-12-15 | Armagen Technologies, Inc. | Agents for blood-brain barrier delivery |
| TWI500427B (zh) | 2010-05-14 | 2015-09-21 | Abbvie Inc | Ｉｌ－１結合蛋白 |
| CN104395344B (zh) * | 2012-05-07 | 2019-08-13 | 达特茅斯大学理事会 | 抗b7-h6抗体、融合蛋白及其使用方法 |
| JP2015536933A (ja) * | 2012-10-23 | 2015-12-24 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Ｗｎｔ経路結合剤を用いて神経内分泌腫瘍を処置する方法 |
| US8684387B1 (en) | 2012-11-26 | 2014-04-01 | NTS Works, Inc. | Cargo cycle steering system |
| WO2014159764A1 (en) * | 2013-03-14 | 2014-10-02 | Amgen Inc. | Chrdl-1 antigen binding proteins and methods of treatment |
| WO2014161037A1 (en) | 2013-04-03 | 2014-10-09 | Peter Maccallum Cancer Institute | Antibodies against human ryk and uses therefor |
| TWI681969B (zh) * | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| CN117295767A (zh) | 2020-11-11 | 2023-12-26 | Versapeutics公司 | 针对wnt受体ryk的抗体变体 |
-
2017
- 2017-03-28 CA CA3039910A patent/CA3039910A1/en active Pending
- 2017-03-28 US US16/086,958 patent/US10899839B2/en active Active
- 2017-03-28 EP EP17776441.2A patent/EP3436476A4/en active Pending
- 2017-03-28 KR KR1020187030913A patent/KR102364249B1/ko active Active
- 2017-03-28 JP JP2018550808A patent/JP7366388B2/ja active Active
- 2017-03-28 WO PCT/US2017/024494 patent/WO2017172733A1/en not_active Ceased
- 2017-03-28 CN CN201780028161.3A patent/CN109563153B/zh active Active
- 2017-03-28 AU AU2017245099A patent/AU2017245099B2/en active Active
-
2020
- 2020-12-18 US US17/127,913 patent/US12134651B2/en active Active
-
2021
- 2021-05-31 AU AU2021203542A patent/AU2021203542B2/en active Active
-
2023
- 2023-06-21 JP JP2023101322A patent/JP2023130369A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12134651B2 (en) | Anti-Ryk antibodies and methods of using the same | |
| Kagiava et al. | AAV9-mediated Schwann cell-targeted gene therapy rescues a model of demyelinating neuropathy | |
| JP5730464B2 (ja) | 延長効果をもつ新規鎮痛治療 | |
| Kim et al. | Nogo-66 receptor prevents raphespinal and rubrospinal axon regeneration and limits functional recovery from spinal cord injury | |
| US20050271655A1 (en) | Nogo receptor antagonists | |
| US10183985B2 (en) | Compositions and methods for rendering tumor cells susceptible to CD8+ T cell-mediated killing | |
| US20080233132A1 (en) | Multiple sclerosis therapy | |
| Young et al. | Adenosine kinase, glutamine synthetase and EAAT2 as gene therapy targets for temporal lobe epilepsy | |
| KR20150018555A (ko) | 뇌졸중 후 신경발생을 촉진시키는 세마포린-４d 결합 분자의 용도 | |
| CN110072888B (zh) | 药剂、用途和方法 | |
| CN1926147A (zh) | Nogo受体拮抗剂 | |
| Hodgetts et al. | Cortical AAV‐CNTF gene therapy combined with intraspinal mesenchymal precursor cell transplantation promotes functional and morphological outcomes after spinal cord injury in adult rats | |
| JP2009517340A (ja) | ドーパミン作動性ニューロンの神経突起成長および生存を促進するための方法 | |
| EA008253B1 (ru) | Антагонисты nogo-рецептора | |
| Baksmeier et al. | Modified recombinant human IgG1‐Fc is superior to natural intravenous immunoglobulin at inhibiting immune‐mediated demyelination | |
| JPWO2020071230A1 (ja) | 融合タンパク質及びその利用 | |
| Duba-Kiss | Developing AAV Gene Therapy Tools for Neurodevelopmental Epileptic Encephalopathies | |
| WO2023238869A1 (ja) | 筋萎縮性側索硬化症、パーキンソン病、ハンチントン病、脊髄小脳失調症、老化に関連する変性疾患若しくは神経疾患、脳老化、あるいは脳老化を伴う疾患の予防剤又は治療剤 | |
| JP2025517248A (ja) | ＳＣＮ１Ａ発現カセットのＣＡＶ－２媒介送達を介して外因性Ｎａｖ１．１活性を提供するためのベクター、組成物、及び方法 | |
| HK40125870A (en) | Preventative agent or therapeutic agent for amyotrophic lateral sclerosis, parkinson’s disease, huntington’s disease, spinocerebellar ataxia, aging-related degenerative or neurological disease, brain aging, or diseases associated with brain aging | |
| Fallon | Pathological implications of the interaction between neurexins and alpha-synuclein in synucleinopathies | |
| KR20060072122A (ko) | Ｎｏｇｏ 수용체 길항제 |